Navigation Links
Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Date:3/19/2008

us iclaprim is also being developed for the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens. This programme is currently in Phase II. Moreover, an oral formulation of iclaprim is currently in Phase II clinical trials as a potential step-down therapy following initial intravenous treatment.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most ad
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Announces Full Year 2007 Financial Results
2. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
5. Arpida-Supported CME Symposium Available Online
6. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Interim Results for six Months to 30 June 2007
11. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Photo-Eyewear™ ( http://www.PhotoEyewear.com ) announced ... Inc. ( http://www.PogoTec.com ) to better reflect the ... and technologies it is developing and plans to commercialize. ... PogoTec™ will provide focused resources to drive key areas ... , On-Track™ – There are well over ...
(Date:6/3/2015)... 2015 Global Stem Cells Group ... announced plans to conduct Romania’s first ever stem cells ... alliance with Miami-based Stem Cell Training, Inc., Cosmetic Surgeon ... and Bone Marrow Stem Cell Training Course for medical ... surgery specialist practicing in Bucharest and Tel Aviv, Israel, ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage ... an agreement whereby the institutional investors will have the ... the Company up to $4.93M in near term funding, ... Under the restructured terms and subject to certain market ... could result in a larger influx of capital to ...
(Date:6/2/2015)... June 02, 2015 Research and Markets ( ... "Bioburden Testing Market by Product , Test, Application & ... their offering. The bioburden testing market is ... Million in 2014, growing at a CAGR of 9.8% ... products, the microbial limit testing market is segmented into ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... Conn., May 20 Biodel Inc. (Nasdaq:,BIOD) today announced ... Chief Medical Officer, effective May 27, 2008., "The ... with strong,internal clinical and regulatory leadership and we expect ... of our product candidates," said,Dr. Solomon Steiner, Chief Executive ...
... McHENRY, Ill., May 20 Turtle Island ... Food soups fortified with ingredients shown to ... ( http://www.ganedenlabs.com/index.html )., The new Souper ... GanedenBC30,(Bacillus coagulans GBI-30, 6086),( http://www.ganedenlabs.com/ourScience.html ), a ...
... of Two-Phase Examination of U.S. Asthma Control, RESEARCH ... half of adult Americans with asthma and more than ... nationally representative survey do,not have their disease well controlled, ... at the International Conference of the American,Thoracic Society meeting ...
Cached Biology Technology:Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer 2Turtle Island Soup Gets 'Souped Up' with New Probiotic, GandenBC30 2Turtle Island Soup Gets 'Souped Up' with New Probiotic, GandenBC30 3Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 2Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows 3
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... The NIH Neuroscience Microarray Consortium today announced that ... Affymetrix and Illumina platforms to its list of ... says that "adding ultra-high throughput genotyping for its ... the Consortium current with the demands of the ...
... Genetics tests could help provide cystic fibrosis (CF) ... authors suggest. Results from a French clinical trial ... small percentage of CF sufferers with a rare ... , Aleksander Edelman and Isabelle Sermet-Gaudelus of Faculté ...
... good with puzzles or chess, the reason may be in ... psychiatric geneticists at Washington University School of Medicine in St. ... a gene that activates signaling pathways in the brain influences ... the gene, CHRM2, and performance IQ, which involves a person's ...
Cached Biology News:NIH neuroscience microarray consortium launches high-throughput genotyping services 2Genes and genius: Researchers confirm association between gene and intelligence 2Genes and genius: Researchers confirm association between gene and intelligence 3
...
... detector for ambient HPLC. Contains connections ... for two external devices such as ... an analog output from the 90 ... recorders. Includes an input for synchronization ...
...
...
Biology Products: